Latest news and press releases about Jaguar Health, Inc. (JAGX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health.
Price
| Price | $0.23 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.03 |
| EV / EBITDA | -0.25 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 762.51% |
| Return on Invested Capital | -109.75% |
| Return on Assets | -107.18% |
| Gross Margin | 82.31% |
| Operating Margin | -90.22% |
| Net Margin | -131.76% |
Related companies: BDRX · CANF · CLDI · CNSP · GNPX · GRI · INM
Explore sector: Healthcare · Biotechnology
More sections of JAGX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks